What You Should Know:
- Catalio Capital Management, LP (“Catalio”), a healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments across the Fund and its related co-investment vehicles.
- Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio currently manages $2B in assets across its private equity, private credit, and public equities
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
LogicFlo AI Secures $2.7M to Optimize Life Sciences with AI Agent Workforce
What You Should Know:
- LogicFlo AI, a pioneering Boston-based startup, today announced it has secured $2.7M in seed funding led by Lightspeed with participation from healthcare and enterprise AI investors.
- The investment will accelerate the deployment of its intelligent agent platform across the pharmaceutical, biotech, and medtech industries. LogicFlo AI aims to free life sciences experts from tedious "busywork" by providing them with AI collaborators for high-stakes,
Read More
Verily and Vanderbilt Extend Partnership to Power NIH’s All of Us Researcher Workbench
What You Should Know:
- Verily and Vanderbilt University Medical Center (VUMC) today announced the continuation of their crucial partnership, ensuring the ongoing success and enhancement of the National Institutes of Health (NIH) All of Us Research Program’s Researcher Workbench platform.
- The extended 5-year collaboration reinforces Verily's role as a key technology partner, providing secure, cloud-based access to invaluable biomedical data for researchers worldwide.
A
Read More
Causaly Launches AI-powered Competitive Intelligence App for Early-Stage Drug Discovery
What You Should Know:
- Causaly today announced Pipeline Graph, giving pharma research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery.
- The AI-powered application lets scientists proactively find and access competitive insights while they evaluate viable drug targets, helping them make confident pipeline decisions faster before investing in costly drug development programs.
Causaly Launches Pipeline Graph to Integrate
Read More
AI in Pharmacovigilance: Why True Transformation Starts with Workflow Re-Engineering
There is no doubt that the introduction of artificial intelligence into the field of pharmacovigilance is making waves. According to a 2025 McKinsey survey of leaders in the pharma and MedTech industries, 32% of life sciences organizations are spending $5 million or more on generative AI budgets. Specifically, there was a 7% increase in the number of respondents expecting to allocate more than $10 million in generative AI budgets, and a 5% increase in respondents planning to spend between $5 and
Read More
The Next Phase of RWE: Why Integration Matters More Than Data Collection
Real-world evidence (RWE) has become central to evaluating therapies, medical products, and health interventions—providing insight into how they perform outside controlled clinical trials. As healthcare systems seek more timely, representative, and cost-effective approaches to evidence generation, real-world data (RWD) is increasingly used to inform regulatory decisions, guide clinical practice, and shape health policy.
As RWE gains traction, fundamental questions remain: How do we ensure
Read More
Caris Life Sciences Announces Pricing of Initial Public Offering
What You Should Know:
- Caris Life Sciences® (Caris), an AI TechBio company and pioneer in precision medicine, today announced the pricing of its initial public offering (IPO) of 23,529,412 shares of its common stock at a public offering price of $21.00 per share.
- The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol “CAI.” The offering is expected to close on June 20, 2025, subject to customary closing
Read More
Omada Health Data Shows Companion Program Significantly Boosts GLP-1 Medication Persistence
What You Should Know:
- Omada Health, the virtual between-visit healthcare provider released new data demonstrating that its GLP-1 companion program significantly improves persistence rates for GLP-1 medications.
- The analysis found that members in Omada's program achieved weight loss results similar to those seen in controlled research settings, underscoring the importance of comprehensive support for individuals on these transformative medications.
- The findings provide
Read More
Quilt Health Raises $6M to Modernize Clinical Trial Access for Complex Diseases
What You Should Know:
- Quilt Health, a digital health company dedicated to bridging gaps in treatment access for complex diseases secures $6M in seed funding round, bringing its total funding to $8M. The round was led by MaC Venture Capital and Underscore Ventures, with participation from Meridian Street Capital, BoxGroup, Watershed VC, and Coalition Operators.
- Founded with an initial focus on sickle cell disease, the company plans to use the new capital to rapidly expand into
Read More
Eliminating Cancer Treatment Side-Effects Through Targeted Drug Delivery
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer cases for the first time in history. This number is staggering and signifies that cancer is truly a disease that impacts many lives each day.
While not all of these cases result in the grueling treatment associated with chemotherapy and radiation, many of those diagnosed will face the difficult road to recovery. Patients in chemotherapy experience a range of symptoms, from
Read More
